Invivyd (NASDAQ:IVVD) Insider Sells $16,095.60 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 22,355 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $0.72, for a total value of $16,095.60. Following the completion of the sale, the insider directly owned 187,362 shares of the company’s stock, valued at $134,900.64. The trade was a 10.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Julie Green also recently made the following trade(s):

• On Tuesday, August 18th, Julie Green sold 18,425 shares of Invivyd stock. The stock was sold at an average price of $0.84, for a total value of $15,477.00.

Invivyd Price Performance

Shares of NASDAQ:IVVD opened at $0.95 on Friday. The business’s 50-day moving average is $0.78 and its 200 day moving average is $1.22. Invivyd, Inc. has a 1 year low of $0.48 and a 1 year high of $3.07. The firm has a market capitalization of $280.26 million, a P/E ratio of -2.88 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The business had revenue of $14.29 million during the quarter, compared to analyst estimates of $14.40 million. On average, analysts expect that Invivyd, Inc. will post -0.51 EPS for the current year.

Hedge Funds Weigh In On Invivyd

A number of hedge funds have recently made changes to their positions in the company. Eventide Asset Management LLC purchased a new position in Invivyd in the 4th quarter valued at $14,349,000. Perceptive Advisors LLC purchased a new position in shares of Invivyd in the fourth quarter worth about $53,809,000. BVF Inc. IL purchased a new position in shares of Invivyd in the fourth quarter worth about $48,227,000. UBS Group AG boosted its position in Invivyd by 683.8% during the fourth quarter. UBS Group AG now owns 1,050,923 shares of the company’s stock worth $2,596,000 after acquiring an additional 916,842 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Invivyd during the second quarter worth about $578,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on IVVD. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a research note on Tuesday. BTIG Research restated a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. Finally, Wall Street Zen lowered Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Invivyd currently has a consensus rating of “Hold” and an average target price of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.